TC 6987
Alternative Names: TC-6987Latest Information Update: 11 Feb 2020
Price :
$50 *
At a glance
- Originator Targacept
- Class Antiasthmatics; Antihyperglycaemics; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Type 2 diabetes mellitus
Most Recent Events
- 05 Feb 2020 Attenua has been acquired and merged into CODA Biotherapeutics
- 02 Aug 2016 Catalyst Biosciences enters into a definitive agreement with Attenua for the divestiture of its neuronal nicotinic receptors
- 31 Dec 2012 Discontinued - Phase-II for Asthma in USA (PO)